12 results about "Viricidal activity" patented technology

This invention relates to recombinant lyases and variants thereof, which have improved stability or bactericidal activity relative to the recombinant lyases. This application also relates to pharmaceutical compositions comprising the recombinant lyases and variants thereof, and their use for the prevention and / or treatment of bacterial infections (e.g., bacterial vaginosis).

The present application relates to a kind of pseudomonas aeruginosa engineering bacteria DUEC construction method and application.The DUEC engineering strain construction method of the present application is: response to kinase coding gene retS and sheath protein coding gene tssB2, tssB3 Knockout, H1-T6SS secretory effector protein Tse1-Tse4, Tse6-Tse8 catalytic site mutation, Tse5 Coding gene knockout.DUEC engineering strain can not only constitutively express and assemble H1-T6SS, but also can respond to adjacent sister cell source T6SS attack, assemble H1-T6SS at the position of being attacked.The present application constructs a series of effector protein combination inactivation mutant by gene knockout or catalytic site mutation method.Microscope observation and statistical analysis results show that no single effector protein is necessary for T6SS attack and assembly.By bacterial competition experiment, it is verified that all effector protein inactivation mutant 8eff c Lose T6SS + Vibrio cholerae and T6SS + Aeromonas dhaka's bactericidal activity, but 8eff c Can respond to T6SS physical attack, Tse6 N -Cre is specifically delivered to T6SS + In Vibrio cholerae.

The present application relates to the field of agricultural technology, and particularly relates to an amine group-containing alstoniascholaris alkaloid derivative, a preparation method and application thereof. The amine group-containing alstoniascholaris alkaloid derivative comprises a compound as shown in formula (I): wherein R comprises at least one of C3-C12 linear alkyl, C3-C12 branched alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C2-C6 aminoalkyl, tetrahydropyrrole group, piperidine group, piperidinylmethyl, N-methylpiperidine group and N-methylpiperidinylmethyl. The amine group-containing alstoniascholaris alkaloid derivative has good plant virus control and good fungicidal activity.

The application discloses application of mulberroside D in synergistic polymyxin antibacterial activity, and belongs to the technical field of medicines, and particularly relates to application of mulberroside D in synergistic polymyxin antibacterial activity. The application discloses application of mulberroside D in preparation of a product for enhancing antibacterial activity and / or bactericidal activity of an antibacterial drug. The mulberroside D can effectively synergize in-vivo and in-vitro antibacterial activity of polymyxin on multi-drug resistant bacteria, can produce synergistic antibacterial effect, and provides a new treatment strategy for clinical treatment of bacterial infectious diseases.

This invention relates to a novel natural microbial metabolite: Fcl-8, derived from the fermentation broth of *Xenorhabdus budapestensis* XBD8. Purified Fcl-8 is a snow-white, flocculent crystal, highly soluble in water, as shown in Figure 1. The chemical structural formula of Fcl-8 is shown in Figure 2, with the chemical formula C1. 57 H 102 N 14 O 12 With a molecular weight of 1175.78744, its typical secondary mass spectrometry information is shown in Figure 3. Fcl-8 is derived from a natural microbial metabolite, has a novel structure and high biological activity, and possesses great potential for development into a novel biopesticide.

The invention discloses a vibrio cantoniensis phage VCP13AVCGD9 as well as a composition and application of the vibrio cantoniensis phage VCP13AVCGD9, the vibrio cantoniensis phage VCP13AVCGD9 is preserved in Guangdong Microbiological Culture Collection Center on November 24, 2025, the preservation number of the vibrio cantoniensis phage VCP13AVCGD9 is GDMCC NO. 67344-B1, and the vibrio cantoniensis phage VCP13AVCGD9 is classified and named as Vibrio campbelli phage VCP13AVCGD9. The vibrio canetinii bacteriophage VCP13AVCGD9 provided by the invention has good acid-base stability, can still keep relatively high titer after being treated for 96 hours under the condition that the pH value is 4.0-8.0, is beneficial to continuously keeping bactericidal activity in a culture water body, and acts on vibrio canetinii in animal gastrointestinal tracts in a targeting manner.

The invention discloses an engineered PVC protein compound for targeted removal of intracellular staphylococcus aureus as well as a preparation method and application of the engineered PVC protein compound, and belongs to the fields of genetic engineering, microbiology and drug delivery. Genetic engineering modification is carried out on PVC, a natural recognition domain of tail fiber protein of the PVC is replaced by a staphylococcus aureus receptor binding structural domain (SRapid BR), and meanwhile, natural toxin protein loaded in an inner cavity of the PVC is replaced by human beta-defensin-3 (HBD-3) with efficient bactericidal activity. The engineered compound can directly deliver HBD-3 into infected cells, effectively remove intracellular staphylococcus aureus which is difficult to kill by conventional antibiotics, and relieve inflammatory response caused by infection. The invention provides a brand-new treatment strategy for resisting intracellular bacterial infection with high targeting, and shows a wide application prospect as a programmable protein delivery platform.

The invention discloses a salmonella paratyphi targeting antibacterial peptide as well as a preparation method and application thereof, and belongs to the field of bioengineering, and the sequence of the antibacterial peptide is as shown in SEQ ID No.1; the invention further discloses application of the antibacterial peptide targeting the salmonella paratyphi to preparation of a medicine for treating salmonella paratyphi infectious diseases. The antibacterial peptide disclosed by the invention has efficient targeted bactericidal activity on salmonella paratyphi, and has no toxicity on human red blood cells, so that the antibacterial peptide has the potential of becoming a feed antibiotic substitute.

The application provides a use of Derazantinib, CAS No. 1234356-69-4, for preparing an anti-Gram-positive bacterial infection drug. The technical scheme of the application discloses a new medical use of Derazantinib. The technical scheme of the application discloses a new medical use of Derazantinib. Derazantinib shows better antibacterial activity on Staphylococcus aureus, can significantly inhibit the formation of a biofilm, and can penetrate a mature biofilm to effectively kill bacteria in the mature biofilm. Derazantinib shows more significant bactericidal activity than vancomycin. In addition, Derazantinib shows strong inhibitory effect on MRSA, MSSA, Enterococcus faecalis and other clinically drug-resistant bacteria.

A composition comprising active ingredient a and active ingredient b, wherein active ingredient a is a compound of the general formula A, and active ingredient b is at least one compound having insecticidal, acaricidal or fungicidal activity which is different from the compound of the general formula A. The composition has the advantages of synergism, broadened spectrum of control, etc. and can be used for controlling various pests (especially mites) and plant diseases caused by various fungi, bacteria, nematodes, viruses.

The present invention relates to a recombinant lyase and a variant thereof. The variant has improved stability or bactericidal activity relative to the recombinant lyase. The present invention also relates to a pharmaceutical composition comprising the recombinant lyase and the variant thereof, and a use thereof in preventing and treating bacterial infections.

A composition and use thereof. The composition comprises an active component a and an active component b; the active component a is a compound as shown in general formula A; and the active component b is at least one of compounds which have insecticidal, acaricidal or bactericidal activity and are different from the compound as shown in general formula A. The composition has the advantages of synergistic effect and expanding prevention and treatment spectrum, and can be used for preventing and treating various pests, particularly mite damage, and plant diseases caused by various fungi, bacteria, nematodes and viruses.